Sutro Biopharma. has been granted a patent for antibodies that specifically target B-cell maturation antigen (BCMA) and its variants. The patent includes methods for therapeutic and diagnostic applications, detailing an isolated IgG class antibody with specific variable region sequences. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of June 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting b-cell maturation antigen (bcma)
The granted patent US11993658B2 describes an isolated antibody of the IgG class that specifically targets B-cell maturation antigen (BCMA). The claims detail the structural components of the antibody, including specific complementarity-determining regions (CDRs) from the heavy and light chain variable regions, identified by SEQ ID numbers. Variants of these regions with up to 20 amino acid substitutions are also included. The patent further specifies that the antibody may contain constant region domains from a defined set of sequences, can be humanized or aglycosylated, and may exist as an antibody fragment, such as an scFv or Fab fragment.
Additionally, the patent outlines the potential applications of the antibody, including its use in pharmaceutical compositions for treating diseases associated with BCMA expression, such as various forms of leukemia, lymphoma, and multiple myeloma. The claims also encompass a kit containing the antibody and instructions for its use. Notably, the antibody is characterized by a specific association rate constant when binding to human BCMA, indicating its potential efficacy in therapeutic applications. Overall, the patent presents a comprehensive framework for the development of BCMA-targeting antibodies for clinical use.
To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
